All Stories

  1. Nanotechnology-Based Platforms for Vaginal Delivery of Peptide Microbicides
  2. Development of a multiplex assay based on chimeric citrullinated peptides as proof of concept for diagnosis of rheumatoid arthritis
  3. Comparative study of the diagnostic and prognostic value of antibodies against chimeric citrullinated synthetic peptides and CCP3/CCP3.1 assays
  4. A study of HIV-1 FP inhibition by GBV-C peptides using lipid nano-assemblies
  5. The Use of Citrullinated Peptides for the Diagnosis and Prognosis of Rheumatoid Arthritis
  6. Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery
  7. A cyclic GB virus C derived peptide with anti-HIV-1 activity targets the fusion peptide of HIV-1
  8. Updating the Use of Synthetic Peptides as Inhibitors of HIV-1 Entry
  9. HIV-1 Inhibiting Capacity of Novel Forms of Presentation of GB Virus C Peptide Domains is Enhanced by Coordination to Gold Compounds
  10. Editorial (Hot Topic:Rheumatoid Arthritis: Current Advances in Pathogenesis, Diagnosis and Therapy)
  11. Citrullinated Peptides in the Diagnosis of Rheumatoid Arthritis
  12. Differences in synovial fluid cytokine levels but not in synovial tissue cell infiltrate between anti-citrullinated peptide/protein antibody-positive and –negative rheumatoid arthritis patients
  13. Design and application of GB virus C (GBV-C) peptide microarrays for diagnosis of GBV-C/HIV-1 co-infection
  14. Oligonucleotide-Peptide Conjugates: Solid-Phase Synthesis under Acidic Conditions and Use in ELISA Assays
  15. Physicochemical characterization of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide: Interaction with model membranes
  16. Anti-citrullinated peptide antibodies in the serum of heavy smokers without rheumatoid arthritis. A differential effect of chronic obstructive pulmonary disease?
  17. Synthetic peptides derived from an N-terminal domain of the E2 protein of GB virus C in the study of GBV-C/HIV-1 co-infection
  18. The Use of Chimeric Vimentin Citrullinated Peptides for the Diagnosis of Rheumatoid Arthritis
  19. Biophysical Investigations of GBV-C E1 Peptides as Potential Inhibitors of HIV-1 Fusion Peptide
  20. Carbon nanotube composite peptide-based biosensors as putative diagnostic tools for rheumatoid arthritis
  21. Effect of E1(64–81) hepatitis G peptide on the in vitro interaction of HIV-1 fusion peptide with membrane models
  22. Analysis of HIV-1 fusion peptide inhibition by synthetic peptides from E1 protein of GB virus C
  23. Diagnostic Value of Anti-GBV-C Antibodies in HIV-Infected Patients
  24. Antibodies against β-fibrin synthetic peptides: A study of their association with the immunogenetic background and disease course of rheumatoid arthritis patients
  25. Synthesis of a New Series of Enkaphalin Related Galactosyl Conjugates
  26. Effect of Synthetic Peptides Belonging to E2 Envelope Protein of GB Virus C on Human Immunodeficiency Virus Type 1 Infection
  27. A Langmuir Monolayer Study of the Interaction of E1(145−162) Hepatitis G Virus Peptide with Phospholipid Membranes
  28. Assessment of synthetic chimeric multiple antigenic peptides for diagnosis of GB virus C infection
  29. Synthetic Peptides of Hepatitis G Virus (GBV-C/HGV) in the Selection of Putative Peptide Inhibitors of the HIV-1 Fusion Peptide
  30. Behaviour of a peptide sequence from the GB virus C/hepatitis G virus E2 protein in Langmuir monolayers: Its interaction with phospholipid membrane models
  31. Fluorescence study of the dynamic interaction between E1(145–162) sequence of hepatitis GB virus C and liposomes
  32. Synthesis and biological activity of substance P analogues
  33. Interaction of GB Virus C/Hepatitis G Virus Synthetic Peptides with Lipid Langmuir Monolayers and Large Unilamellar Vesicles
  34. Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis
  35. Peptide-Based Diagnostic Assays
  36. Liposome destabilization induced by synthetic lipopeptides corresponding to envelope and non-structural domains of GBV-C/HGV virus. Conformational requirements for leakage
  37. Antibodies to Citrullinated Human Fibrinogen Synthetic Peptides in Diagnosing Rheumatoid Arthritis
  38. Synthesis of Overlapping Fibrin Citrullinated Peptides and their use for Diagnosing Rheumatoid Arthritis
  39. Interfacial Properties of a Synthetic Peptide Derived from Hepatitis G Virus E2 Protein:  Interaction with Lipid Monolayers
  40. Characterization of a putative fusogenic sequence in the E2 hepatitis G virus protein
  41. Interaction of synthetic peptides corresponding to hepatitis G virus (HGV/GBV-C) E2 structural protein with phospholipid vesicles
  42. Perturbations induced by synthetic peptides from hepatitis G virus structural proteins in lipid model membranes: a fluorescent approach
  43. Analysis of the effect of a peptide sequence of the E2 protein (HGV/GBV-C) on the physicochemical properties of zwitterionic and negatively charged bilayers
  44. Design of Synthetic Peptidic Constructs for the Vaccine Development Against Viral Infections
  45. Effects of Overlapping GB Virus C/Hepatitis G Virus Synthetic Peptides on Biomembrane Models
  46. Interaction of three β-interferon domains with liposomes and monolayers as model membranes
  47. Study in mono and bilayers of the interaction of hepatitis G virus (GBV-C/HGV) synthetic antigen E2(99-118) with cell membrane phospholipids
  48. Interaction of Antimicrobial Arginine-Based Cationic Surfactants with Liposomes and Lipid Monolayers
  49. Peptides and Liposomes: From Biophysical to Immunogenic Studies
  50. GB Virus C (GBV-C) / Hepatitis G Virus (HGV): Towards the Design of Synthetic Peptides-based Biosensors for Immunodiagnosis of GBV-C / HGV Infection
  51. Liposome entrapment and immunogenic studies of a synthetic lipophilic multiple antigenic peptide bearing VP1 and VP3 domains of the hepatitis A virus: a robust method for vaccine design
  52. Miscibility of Hepatitis A Synthetic Antigen Peptides with Lipid Monolayers:  Effect of the Amino Acid Sequence Change
  53. Synthesis and surface activity measurements of HGV NS3 (513–522) peptide and its palmitoyl derivative
  54. Use of [Cit312,314] filaggrin (306–324) analogue for the diagnosis of rheumatoid arthritis. Conformational study by circular dichroism and fourier transformed infrared spectroscopy
  55. Interfacial Interactions of Hydrophobic Peptides with Lipid Bilayers
  56. Hydrophobic Laminin-Related Peptides: Synthesis and Surface Properties
  57. Phospholipid−Model Membrane Interactions with Branched Polypeptide Conjugates of a Hepatitis a Virus Peptide Epitope
  58. Enhancement of the immunogenicity of a synthetic peptide bearing a VP3 epitope of hepatitis A virus
  59. Conformational behavior of the HAV-VP3(110–121) peptidic sequence and synthetic analogs in membrane environments studied by CD and computational methods
  60. Conformational behavior of the HAV‐VP3(110–121) peptidic sequence and synthetic analogs in membrane environments studied by CD and computational methods
  61. A new continuous epitope of hepatitis A virus
  62. Physicochemical study of laminin-related peptides
  63. Interactions of a tetravalent branched peptide from VP3 capsid protein of hepatitis A virus with monolayers as biomembrane models
  64. Conformational study of the preferred conformations of the peptide sequence VP3(110–121) of HAV by circular dichroism and molecular mechanics
  65. Anti-Hepatitis A Virus Antibody Response Elicited in Mice by Different Forms of a Synthetic VP1 Peptide
  66. Physicochemical study of hepatitis A and B peptide fragments with monolayers as membrane models
  67. Solid phase synthesis of potential antigenic peptides and new lipopeptides of hepatitis B virus
  68. A Synthetic Glycopeptide of Substance P Analogue (SP6–11) with Enhanced NK-1 Receptor Specificity
  69. In vitro activity and selectivity of glucosidic SP(66-11) analogues
  70. Hydrophobic peptides: Synthesis and interaction with model membranes